MACOMTechnology

MACOM Technology: JP Morgan raises PT to $240 from $165, maintains Neutral rating.

MACOM Technology's 15min chart triggers MACD Death Cross, KDJ Death Cross.

MACOM Technology shares rise 5.36% intraday after Benchmark and others raise price targets to $260-$255, citing strong Q1 revenue and profit growth.

Stifel Reiterates Buy Rating for MACOM Technology, Raises PT to $255

MACOM Technology: Truist Securities Maintains Buy, PT Raised to $261 from $200

Catalyst<ul> <li>Most analysts rate MTSI Buy or Strong Buy, showing broad institutional optimism.</li> <li>The company maintains strong cash reserves relative to market value.</li> <li>Recent Long Lower Shadow signals in late January and early February indicate strong bullish momentum for MTSI.</li></ul>Risk<ul> <li>Technical indicators show that the market is in a volatile state, and the direction is not clear enough.</li> <li>Fund flow analysis indicates that overall trends are negative, with small and medium-sized orders showing outflows.</li> <li>MACD Death Cross signals in early February suggest a biased bearish outlook for MTSI.</li></ul>

Key Factors

MACOM Technology Solutions (MTSI) reported Q1 2026 revenue of $271.6 million, up 24.5% year-over-year. MTSI shares rose 6.00% in after-hours trading following strong Q1 earnings and raised Q2 guidance. Benchmark, Stifel, Needham, and Truist raised MTSI price targets between $250 and $261, citing strong Q1 performance and growth potential. Stephen Ferranti and Dr. Gregg Jessen were promoted to senior leadership roles at MTSI to strengthen corporate development and GaN technology initiatives.

MTSI News